Company profile for Quadriga BioSciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Gordon is a biotechnology entrepreneur. Quadriga is an oncology start-up focused on developing targeted anti-cancer drugs. He is currently on the board of directors for Maverix Biomics, a bio-informatics company co-founded by Prof Todd Lowe (UCSC) and is on the board of directors of Ardelyx, Alexza, and 3V Biopharma.. From 1997 to 2015, he served in various capacities as Co-Founder and/or CEO of Maxygen, SurroMed, Alexza, and...
Gordon is a biotechnology entrepreneur. Quadriga is an oncology start-up focused on developing targeted anti-cancer drugs. He is currently on the board of directors for Maverix Biomics, a bio-informatics company co-founded by Prof Todd Lowe (UCSC) and is on the board of directors of Ardelyx, Alexza, and 3V Biopharma.. From 1997 to 2015, he served in various capacities as Co-Founder and/or CEO of Maxygen, SurroMed, Alexza, and Alavita. From 1991 to 2000, Gordon was CEO and Scientific Director of Affymax Research Institute (acquired by Glaxo in 1995) where he managed the development of novel technologies

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
339 S. San Antonio Road, Suite 2A Los Altos, CA 94022
Telephone
Telephone
+ 1 (650) 917 9098
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

IPhEB Russia

Not Confirmed

envelop Contact Supplier

IPhEB Russia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/quadriga-biosciences-announces-encouraging-interim-phase-ii-results-of-lat1-targeted-qbs72s-in-breast-cancer-patients-with-leptomeningeal-disease-302631417.html

PR NEWSWIRE
03 Dec 2025

https://www.prnewswire.com/news-releases/quadriga-biosciences-announces-dosing-of-first-subject-in-phase-2-study-evaluating-qbs72s-for-brain-metastases-of-breast-cancer-301793626.html

PR NEWSWIRE
11 Apr 2023

https://www.clinicaltrialsarena.com/news/quadriga-solid-tumour-trial/

CLINICALTRIALSARENA
26 Oct 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty